The historical rank and industry rank for Paradigm Biopharmaceuticals's PB Ratio or its related term are showing as below:
PBIGF'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 14.71
Current: 14.71
During the past 10 years, Paradigm Biopharmaceuticals's highest PB Ratio was 14.71. The lowest was 0.00. And the median was 0.00.
PBIGF's PB Ratio is ranked worse than 88.07% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs PBIGF: 14.71
During the past 12 months, Paradigm Biopharmaceuticals's average Book Value Per Share Growth Rate was -83.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -32.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -35.70% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Paradigm Biopharmaceuticals was 55.40% per year. The lowest was -40.90% per year. And the median was -24.90% per year.
Back to Basics: PB Ratio
Paradigm Biopharmaceuticals (OTCPK:PBIGF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Paradigm Biopharmaceuticals PB Ratio Related Terms
Paradigm Biopharmaceuticals PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Paradigm Biopharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paradigm Biopharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Paradigm Biopharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Paradigm Biopharmaceuticals (PBIGF) has a PB Ratio of 16.34 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Paradigm Biopharmaceuticals and its competitors. According to the industry distribution chart, Paradigm Biopharmaceuticals ranks #1085 out of 1232 companies in the Biotechnology industry, placing it in the top 88.1%.
Is Paradigm Biopharmaceuticals' PB Ratio too high?
Paradigm Biopharmaceuticals' current PB Ratio is 16.34. The Biotechnology industry median PB Ratio is 2.80. Paradigm Biopharmaceuticals' value of 16.34 is 483.6% above this industry median. Based on the distribution chart, Paradigm Biopharmaceuticals ranks #1085 out of 1232 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Paradigm Biopharmaceuticals ranks #1085 out of 1232 companies for PB Ratio. This places Paradigm Biopharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.80. Paradigm Biopharmaceuticals' value of 16.34 is 483.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paradigm Biopharmaceuticals's current PB Ratio of 16.34 is 483.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Paradigm Biopharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paradigm Biopharmaceuticals's current PB Ratio is 16.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (PBIGF) has a current PB Ratio of 16.34. The current PB Ratio is 16.34 and 483.6% above the Biotechnology industry median of 2.80. Paradigm Biopharmaceuticals' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (PBIGF), the current PB Ratio is 16.34 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
18GF Score
Get the complete analysis for PBIGF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBIGF has been successfully added to your 
